Mount Sinai Careers
Please enter a valid email.
Unfortunately, our network is not responding. Please try again later.
Your job alert was successfully created.
in pursuing bio-behavioral research in the prevention and control of aversive reactions to
cancer and its treatment. Our current research focuses on understanding and treating
cancer-related fatigue, depression, cognitive impairment, and sleep problems. These prob-
lems are among the most aversive that patients and survivors experience. Such symptoms
can occur before, during and even years after the completion of all medical treatment.
Current research indicates that disruption of circadian rhythms may underlie this cluster
of aversive symptoms. We have promising evidence that systematic bright light exposure
(sLE), similar to that used in the treatment of Season Affective Disorder, can effectively
prevent and control such problem through the entrainment of circadian rhythms. These re-
sults have broad implications across many cancers as well as for neurodegenerative disorders
such as Alzheimers, Parkinsons and Multiple Sclerosis; all hypothesized to share disruption
of circadian rhythms. We have recently receive four separate NIH research awards to in-
vestigate: 1) sLE to treat cancer related fatigue and depression in survivors of stem cell
transplantation in the treatment of Multiple Myeloma and Lymphoma; 2) sLE to treat
cognitive impairment in cancer survivors; 3) sLE during adjuvant chemotherapy for breast
cancer to prevent the development of fatigue, depression and cognitive impairment; and
4) biological mediators of the effects of sLE. In addition to efficacy trials, we are now
planning a large national study of sLE effectiveness among cancer survivors. This research
effort represents the collaboration of investigators from Icahn School of Medicine, Memorial
Sloan-Kettering Cancer Center, University of California at San Diego, University of Iowa,
Rensselaer Polytechnic Institute, Northwestern University, and the University of Reykjavik
(Iceland). Post doctoral fellows will be actively included as collaborators in this exciting line
of research, including: carrying out clinical trials and biological mechanism explorations,
planning and writing research proposals and reports, presenting at professional conferences
and spearheading dissemination efforts.
The senior mentor of this two-year fellowship is William H. Redd, PhD, who has trained a
large number of leaders in the field and has been recognized for his excellence in mentoring
by the Society of Behavioral Medicine, his leadership by the American Psychosocial Oncol-
ogy Society and his lifetime of scientific achievements by the International Psycho-Oncology
Applicants with Ph.D, MD or equivalent in any field including biology, neurosciences, engineering and psychology (clinical, experimental and physiological).